Sisäpiiritieto: Rush
Sisäpiiritieto: Rush Factory Oyj suomalainen tytäryhtiö on asetettu konkurssiin
November 22, 2024 03:04 ET | Rush Factory Oyj
Rush Factory Oyj 22.11.2024 Sisäpiiritieto: Rush Factory Oyj suomalainen tytäryhtiö on asetettu konkurssiin Rush Factory Oyj:n kokonaan omistama tytäryhtiö Funrun Finland Oy on asetettu...
Mawson_Black (1).png
Mawson Infrastructure Group Inc. to Ring the Closing Bell at NASDAQ
November 21, 2024 08:00 ET | Mawson Infrastructure Group Inc.
MIDLAND, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson” or “the Company”), a publicly-traded technology company focused on digital infrastructure...
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
November 21, 2024 05:30 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
XXXX.png
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
November 20, 2024 08:30 ET | Silexion Therapeutics Corp
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers,...
New Logo.png
LuxUrban Hotels Inc. Signs A Non-Binding Letter of Intent for Proposed Joint Venture with Lockwood Development Partners LLC and The Bright Hospitality Management to Elevate Hotel Operations and Guest Experience
November 20, 2024 08:00 ET | LuxUrban Hotels Inc.
LuxUrban Hotels Inc. Signs A Non-Binding Letter of Intent for Proposed Joint Venture with Lockwood Development Partners LLC
PasitheaLogo.png
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
November 20, 2024 07:02 ET | Pasithea
Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile.
New Logo.png
LuxUrban Hotels Inc. Reports Third Quarter 2024 Financial Results
November 20, 2024 07:00 ET | LuxUrban Hotels Inc.
LuxUrban Hotels Inc. Reports Third Quarter 2024 Financial Results
James (Josh) Wilson Faruqi & Faruqi, LLP
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Xiao-I Corporation
November 18, 2024 22:03 ET | Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Xiao-I To Contact Him Directly To Discuss Their Options If you...
James (Josh) Wilson Faruqi & Faruqi, LLP
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lilium N.V.
November 18, 2024 21:52 ET | Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Lilium To Contact Him Directly To Discuss Their Options If you...
James (Josh) Wilson Faruqi & Faruqi, LLP
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ASML
November 18, 2024 21:18 ET | Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 in ASML To Contact Him Directly To Discuss Their Options If you...